Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Still a Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $11.21 and last traded at $11.15, with a volume of 1805901 shares traded. The stock had previously closed at $9.16.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TBPH shares. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $11.33.

Theravance Biopharma Trading Down 1.0%

The company's 50 day simple moving average is $9.23 and its 200 day simple moving average is $9.37. The stock has a market capitalization of $550.51 million, a PE ratio of -10.90 and a beta of -0.10.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. As a group, analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.90% of the company's stock.

Institutional Trading of Theravance Biopharma

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its position in Theravance Biopharma by 3.5% during the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock valued at $433,000 after acquiring an additional 1,576 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Theravance Biopharma by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 1,720 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Theravance Biopharma by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares during the period. Rhumbline Advisers increased its position in Theravance Biopharma by 3.8% during the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock worth $556,000 after purchasing an additional 2,293 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Theravance Biopharma in the fourth quarter valued at approximately $25,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.